This activity is supported by an educational grant from Lilly and Merck.

Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer

Lee S. Schwartzberg, MD, FACP
West Cancer Center

Heather Greene, FNP, AOCNP®
West Cancer Center

The standard treatment approach for ER+ breast cancer includes surgery, radiation, or both, along with chemotherapy, endocrine therapy, targeted therapy, or combinations of these approaches. Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. The major side effect is hematologic toxicity, however, this differs from the hematologic effects associated with conventional cytotoxic chemotherapy. This educational program will provide advanced practitioners valuable insight into the science behind CDK inhibition, when CDKs are indicated, how to monitor for and manage side effects, as well as when and how to dose adjust.



 

Download Podcast

   To claim credit for podcast click here
 
 

Download Transcript

 
 

Download Slides

 
 

Download Slides & Transcripts

   To claim credit for the slides & transcript click here





These CE/CME/CEU accredited activities are jointly provided by

JADPRO Logo    Harborside Press Logo    APSHO Logo    Annenberg Logo
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here